BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

Search

Sanofi SA

Uždarymo kaina

SektoriusSveikatos priežiūra

92.54 -0.88

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

92.18

Max

94.26

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-2.3B

499M

Pardavimai

-6.5B

7.6B

P/E

Sektoriaus vid.

20.663

57.333

Pelnas, tenkantis vienai akcijai

1.31

Dividendų pajamingumas

4.32

Pelno marža

6.539

Darbuotojai

82,878

EBITDA

-3.7B

563M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+22.28% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

4.32%

2.63%

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-20B

111B

Ankstesnė atidarymo kaina

93.42

Ankstesnė uždarymo kaina

92.54

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Neutral Evidence

Sanofi SA Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-04-24 08:52; UTC

Uždarbis

Sanofi Sales, Profit Beat Expectations on Higher Demand for Skin, Asthma Drug -- Update

2025-04-24 05:44; UTC

Uždarbis

Sanofi Sales, Profit Beat Expectations

2025-04-09 06:00; UTC

Įsigijimai, susijungimai, perėmimai

Santander Exploring Options to Sell Polish Unit Stake, Bloomberg Says, Citing Sources

2025-03-20 06:43; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi to Acquire Autoimmune Disease Treatment From Dren Bio for Up to $1.9 Billion

2025-04-24 12:54; UTC

Rinkos pokalbiai
Uždarbis

Sanofi's Pipeline Updates Seem Mixed -- Market Talk

2025-04-24 10:06; UTC

Rinkos pokalbiai
Uždarbis

Sanofi Starts the Year Strong -- Market Talk

2025-04-10 12:06; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

PKO's Hypothetical Acquisition of Santander's Polish Unit Could Increase Its Role in Sector -- Market Talk

2025-04-10 09:10; UTC

Karštos akcijos

Stocks to Watch Thursday: Trump Media, U.S. Steel, Tesla, Barclays -- WSJ

2025-04-09 10:49; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Erste Bank Seen as Potential Buyer for Santander's Polish Unit -- Market Talk

2025-04-09 08:19; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Capital Deployment From Santander's Potential Poland Disposal Is Key Question -- Market Talk

2025-04-09 06:59; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Potential Santander Polish Exit Less Compelling Than Sale of U.K. Bank -- Market Talk

2025-04-09 06:46; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Santander's Potential Polish Operations Disposal Could Free Up Capital to Boost Returns Elsewhere -- Market Talk

2025-04-04 09:07; UTC

Karštos akcijos

Stocks to Watch Friday: Glencore, Apple, Barclays -- WSJ

2025-04-03 07:51; UTC

Rinkos pokalbiai

Big Pharma Stocks Rise After Exclusion From U.S. Tariffs -- Market Talk

2025-04-02 13:44; UTC

Rinkos pokalbiai

Santander Push Into Canada on the Cards -- Market Talk

2025-04-02 09:27; UTC

Karštos akcijos

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

2025-03-26 06:19; UTC

Rinkos pokalbiai
Uždarbis

Santander Surpasses 100 Billion-Euro Valuation Milestone -- Market Talk

2025-03-25 10:08; UTC

Rinkos pokalbiai

Santander Needs Step-Up in Profitability to Fully Close Discount -- Market Talk

2025-03-20 09:00; UTC

Svarbiausios naujienos

'Anti-Woke' in the U.S., DEI at Home: the New Playbook for European Companies -- WSJ

2025-03-20 06:05; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi: Deal Seeks to Broaden Immunology Pipeline

2025-03-20 06:05; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi to Make Potential Future Payments Totaling $1.3B Upon Reaching Milestones

2025-03-20 06:04; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi to Pay $600M Upfront

2025-03-20 06:02; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi to Buy Dren Bio's Bispecific Myeloid Cell Engager

2025-03-20 06:00; UTC

Įsigijimai, susijungimai, perėmimai

Press Release: Sanofi To Acquire Dren Bio's Bispecific Myeloid Cell Engager For Deep B-cell Depletion, Broadening Immunology Pipeline >SAN.FR

2025-03-18 09:33; UTC

Karštos akcijos

Stocks to Watch Tuesday: Nvidia, BYD, Santander, Google -- WSJ

2025-03-17 23:00; UTC

Svarbiausios naujienos

Santander Pushes to Expand U.S. Operations by Utilizing Verizon Customer Base -- WSJ

2025-03-13 09:50; UTC

Uždarbis

Santander Approves Final Cash Dividend Per Share of EUR11 cents

2025-03-13 09:49; UTC

Uždarbis

Santander Increased 2024 Cash Payments by 19%

2025-02-24 08:56; UTC

Rinkos pokalbiai
Uždarbis

European Banks' Quarterly Beats Confirm Momentum -- Market Talk

2025-02-24 08:30; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Southern European Banks' Strong Finish to 2024 Confirms Attractiveness -- Market Talk

Akcijų palyginimas

Kainos pokytis

Sanofi SA Prognozė

Kainos tikslas

By TipRanks

22.28% į viršų

12 mėnesių prognozė

Vidutinis 114.144 EUR  22.28%

Aukščiausias 127 EUR

Žemiausias 83.729 EUR

Remiantis 14 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Sanofi SA kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

14 ratings

10

Pirkti

4

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

91.62 / 93.4Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Neutral Evidence

Vidutinės trukmės periodas

Strong Bearish Evidence

Ilgalaikis periodas

Strong Bearish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Sanofi SA

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.